Confirm the hereditary diagnosis and build a family pathway
A pathogenic VHL germline variant confirms the syndrome and has implications for first-degree relatives. Genetic counseling should address autosomal-dominant inheritance, testing of at-risk relatives and the age-appropriate start of surveillance. A new apparently solitary hemangioblastoma can also trigger genetic assessment, especially at younger age or when there are multiple lesions or other VHL manifestations.
VHL surveillance is lifelong and multisystem
A useful surveillance plan coordinates CNS imaging, retinal examinations, abdominal imaging, blood-pressure and biochemical assessment for pheochromocytoma, hearing-related evaluation when an endolymphatic sac tumor is suspected and organ-specific follow-up. The exact interval varies with age, previous tumors, growth kinetics and treatment history. Freiburg publishes an integrated VHL pathway across neurosurgery, nephrology, genetics, ophthalmology and other specialties.
CNS hemangioblastomas are often observed until treatment is justified
Hemangioblastomas are histologically benign but highly vascular tumors that can occur in the cerebellum, brainstem and spinal cord. VHL patients often develop multiple lesions over time, so automatic removal of every MRI-visible tumor would create unnecessary cumulative surgical burden. Symptoms, tumor or cyst growth, mass effect, location and future neurological risk guide the timing of intervention.
Microsurgery remains important for symptomatic or strategically risky hemangioblastomas
When a CNS hemangioblastoma needs local treatment, microsurgical resection is a key option. Experienced centers plan surgery around the lesion's vascular anatomy and neurological location. Freiburg describes selective use of intraoperative ICG videoangiography, minimally invasive approaches for suitable lesions and preoperative embolization for selected large solid vascular tumors.
Belzutifan adds a systemic option for selected adults
Welireg (belzutifan) inhibits HIF-2α and is authorized in the EU for adults with VHL disease who require treatment for associated localized renal cell carcinoma, CNS hemangioblastomas or pancreatic neuroendocrine tumors when localized procedures are unsuitable. This is not a universal replacement for surgery or surveillance. Selection depends on tumor distribution, urgency, prior procedures, expected organ preservation and treatment risks.
Belzutifan requires active safety monitoring
EMA product information identifies anemia and hypoxia among important treatment risks, with other common adverse effects including fatigue, nausea, dyspnea and dizziness. Baseline blood counts, oxygenation, comorbidities, drug interactions, pregnancy prevention and repeated monitoring need to be reviewed by the treating oncology/VHL team. Severe or urgent mass effect may still require local treatment rather than waiting for systemic response.
Renal cell carcinoma management should protect kidney function across a lifetime
VHL-associated clear-cell renal tumors may be bilateral or recurrent. Surveillance, nephron-sparing surgery, ablation and systemic treatment questions should therefore be discussed with VHL-experienced nephrology/urology teams rather than approached as a single sporadic kidney tumor. The long-term objective includes cancer control while preserving renal function and avoiding avoidable cumulative procedures.
Pancreatic and adrenal manifestations require separate specialist decisions
Pancreatic cysts are common, while pancreatic neuroendocrine tumors require risk assessment based on size, growth and other tumor characteristics. Pheochromocytoma requires biochemical/endocrine evaluation and careful perioperative planning when treatment is indicated. These manifestations are not managed by neurosurgery and reinforce the need for a coordinated VHL center.
Retinal hemangioblastomas can threaten vision before neurological symptoms appear
Dilated retinal examination is a core VHL surveillance component. Retinal lesions may require ophthalmic laser, cryotherapy or other treatment depending on size and location. Visual symptoms should prompt timely ophthalmological assessment; CNS MRI cannot substitute for retinal surveillance.
Freiburg provides a dedicated multidisciplinary VHL pathway
University Medical Center Freiburg publishes separate VHL clinics in neurosurgery and nephrology and coordinates genetics, ophthalmology, radiology, urology and other specialties. Its neurosurgical program reports nationwide referral for hemangioblastoma/VHL care and explicitly describes microsurgery, surveillance and current belzutifan review in cooperation with the nephrology VHL clinic.
What to send for a German VHL second opinion
A useful review needs the longitudinal tumor map, not only the newest lesion.
- Full VHL genetic report and family history
- Brain and spine MRI DICOM files with serial reports
- Ophthalmology/retinal examination reports
- Abdominal MRI or CT showing kidneys, pancreas and adrenals
- Renal surgery, ablation or pathology reports
- Pheochromocytoma biochemical/endocrine records if relevant
- Pancreatic NET imaging/pathology if present
- Audiology or temporal-bone imaging for suspected endolymphatic sac tumor
- Current and previous belzutifan or other systemic therapy records
- Renal function, blood count and oxygenation data when systemic therapy is being considered
- Exact question: surveillance plan, CNS surgery, kidney-preserving treatment, belzutifan candidacy, retinal care or multidisciplinary coordination
Urgent complications should be treated locally
New severe neurological deficits, reduced consciousness, acute hydrocephalus, major tumor hemorrhage, severe hypertension with suspected pheochromocytoma crisis, acute visual loss or other rapidly progressive symptoms require urgent local or tertiary care. Planned international travel should not delay emergency treatment.
Official sources
Sources last checked 2026-09-03. Clinical pathways, eligibility and hospital procedures can change; confirm current requirements directly with the treating center.
- Freiburg VHL clinic — University Medical Center Freiburg ↗
- Freiburg hemangioblastoma and VHL neurosurgery program — University Medical Center Freiburg ↗
- Freiburg English VHL/hemangioblastoma program — University Medical Center Freiburg ↗
- Welireg (belzutifan) EPAR — European Medicines Agency ↗
- Hemangioblastoma and VHL: genetic background, disease spectrum and neurosurgical treatment — Child's Nervous System / Freiburg multidisciplinary authors ↗